Digest Network Come funziona
Network
/
Società
Ph
Non verificato

PharmaEssentia USA Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

19 comunicati stampa

Guarda tutti i comunicati
06/11/2026
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
PharmaEssentia to Present Additional BESREMi® Data Across Polycythemia Vera and Essential Thrombocythemia at ASH 2026
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
02/11/2026
Eventi
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
19/10/2026
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
09/09/2026
Eventi
Fiere
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
31/08/2026
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
26/06/2026
Industria
Scienza
Attrezzature medico-sanitarie
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
10/06/2026
Industria
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
22/05/2026
Eventi
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
27/01/2026
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Attrezzature medico-sanitarie
Medicina - Varie
Sanità
Industria
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0
13/01/2026
Igiene alimentare
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Fonte
PharmaEssentia USA Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0